Quantification of sunitinib and n-desethyl sunitinib in human edta plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: Validation and application in routine therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 168-176

  Lankheet, Nienke A G ^a   Steeghs, N ^b   Rosing, H ^a   Schellens, J H M ^b,c   Beijnen, J H ^a,c   Huitema, A D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c Beta Faculty   (Netherlands)

Author keywords

HPLC MS MS; N desethyl sunitinib; therapeutic drug monitoring

Indexed keywords

EDETIC ACID; N DEETHYLSUNITINIB; SUNITINIB;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MONITORING; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

CHROMATOGRAPHY, LIQUID; DRUG MONITORING; EDETIC ACID; HUMANS; INDOLES; PYRROLES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84875200447     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31827efd9e     Document Type: Article

References (28)

1. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-1338.
2. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24.
3. Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010; 66: 357-371.
4. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003; 2: 1011-1021.
5. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and plateletderived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2: 471-478.
6. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006; 24: 25-35.
7. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-337.
8. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003; 20: 757-766.
9. de Jonge ME, Huitema AD, Schellens JH, et al. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005; 44: 147-173.
10. Ivanova M, Artusi C, Polo G, et al. High-throughput LC-MS/MS method for monitoring sirolimus and everolimus in the routine clinical laboratory. Clin Chem Lab Med. 2011; 49: 1151-1158.
11. Baratté S, Sarati S, Frigerio E, et al. Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004; 1024: 87-94.
12. Blanchet B, Saboureau C, Benichou AS, et al. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta. 2009; 404: 134-139.
13. de Bruijn P, Sleijfer S, Lam MH, et al. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2010; 51: 934-941.
14. Etienne-Grimaldi MC, Renee N, Izzedine H, et al. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 3757-3761.
15. Haouala A, Zanolari B, Rochat B, et al. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 1982-1996.
16. Honeywell R, Yarzadah K, Giovannetti E, et al. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878: 1059-1068.
17. Lankheet NA, Blank CU, Mallo H, et al. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. J Anal Toxicol. 2011; 35: 558-565.
18. Minkin P, Zhao M, Chen Z, et al. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 874: 84-88.
19. Rodamer M, Elsinghorst PW, Kinzig M, et al. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879: 695-706.
20. Zhou Q, Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 2010; 51: 958-964.
21. European Medicines Agency (EMA). Guideline on bioanalytical method validation. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2011/08/WC500109686.pdf. Accessed November 16, 2011.
22. U.S. Food and Drug Administration: Centre for Drug Evaluation and Research. Guidance for industry: bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/UCM070107.pdf. Accessed March 21, 2011.
23. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007; 24: 1962-1973.
24. Steeghs N. Use of individual pharmacokinetically (PK)-guided sunitinib dosing: a feasibility study in patients with advanced solid tumors (NCT01286896). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01286896? term=NCT01286896&rank=1. Accessed March 21, 2012.
25. Clinical and Laboratory Standards Institute (CLSI). Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline. 2nd ed. 2002. Available at: http://www.jslab.cn/data/2006/EP09-A2.pdf. Accessed March 21, 2012. NCCLS document EP9-A2.
26. Sistla A, Shenoy N. Reversible Z-E isomerism and pharmaceutical implications for SU5416. Drug Dev Ind Pharm. 2005; 31: 1001-1007.
27. Sparidans RW, Iusuf D, Schinkel AH, et al. Liquid chromatographytandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 4090-4096.
28. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 2007; 9: E109-E114.